Skip to main content
. Author manuscript; available in PMC: 2022 Apr 6.
Published in final edited form as: Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Apr 3;3(11):916–926. doi: 10.1016/j.bpsc.2018.03.014

Table 1.

Demographics

HV (n=36) PSZ (n=42) t/X2 p
Age 42.81 (8.86) 44.60 (8.26) −.92 .36
Gender [F, M] [12, 24] [13, 29] .05 .82
Race
African American, Caucasian, Other [11,24,1] [13,25,4] 2.74 .60
Education level (years) 14.86 (1.99) 12.69 (2.20) 4.49 <.001
Maternal education level 13.60 (2.19) 13.46 (2.51) .25 .80
Paternal education level 13.29 (3.05) 13.89 (4.20) −.70 .48
WASI-II IQ score 114.86 (10.59) 98.10 (14.89) 5.76 <.001
MATRICS Domains
Processing Speed 54.66 (9.47) 35.12 (11.57) 7.99 <.001
Attention/Vigilance 51.77 (11.47) 41.45 (12.44) 3.75 <.001
Working Memory 54.23 (10.16) 38.02 (11.13) 6.62 <.001
Verbal Learning 50.11 (10.58) 36.69 (8.10) 6.30 <.001
Visual Learning 45.46 (11.23) 35.02 (13.49) 3.64 <.001
Reasoning 53.84 (9.99) 43.02 (9.64) 4.82 <.001
Social Cognition 50.91 (8.93) 36.83 (11.12) 6.04 <.001
Antipsychotic Medication
Total Chlorpromazine - 332.36 (424.21) - -
Total Haloperidol - 6.88 (9.10) - -
Clinical Ratings
BPRS Positive (sum) - 9.30 (5.37) - -
SANS AA/RF (sum) - 17.00 (7.73) - -
SANS AFB/Alog (sum) - 10.67 (7.89) - -
*

MATRICS ratings and IQ score missing for 1 HV

*

M Education missing for 1 HV and 5 PSZ

*

P Education missing for 1 HV and 4 PSZ

*

CPZ/Haldol missing for 1 PSZ